Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers
Cancers · 24.12.2023 · 16 (1) · 103
DOI: 10.3390/cancers16010103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.12.2023. Verfasst von Taoran Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong 999077, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SIRG - CityU Strategic Interdisciplinary Research Grant, SIRG—the CityU Strategic Interdisciplinary Research Grant.
Abstract (Originalsprache)
Background
Hereditary breast and ovarian cancers (HBOCs) pose significant health risks worldwide and are mitigated by prophylactic interventions. However, a meta-analysis of their efficacy and the impact of different genetic variants on their effectiveness is lacking.
Methods
A systematic review and meta-analysis were conducted, adhering to Cochrane guidelines. The review encompassed studies that involved prophylactic interventions for healthy women with BRCA variants, focusing on cancer incidence and mortality outcomes. The Newcastle–Ottawa Scale was used for risk of bias assessment. We pooled the extracted outcomes using random effects models and conducted subgroup analyses stratified by intervention, variant, and cancer types.
Results
A total of 21 studies met the inclusion criteria. The meta-analysis revealed that prophylactic interventions significantly reduced cancer risk and mortality. The subgroup analysis showed a greater protective effect for BRCA2 than BRCA1 variant carriers. Risk-reducing surgeries (RRS) were more effective than chemoprevention, with RRS notably reducing cancer risk by 56% compared to 39% for chemoprevention. Prophylactic oophorectomy significantly reduced HBOC risks, while the effect of prophylactic mastectomy and chemoprevention on mortality was less conclusive.
Conclusions
Prophylactic interventions significantly reduce the risk of HBOC and associated mortality. This comprehensive analysis provides insights for future economic evaluations and clinical decision-making in HBOC interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong 999077, China.
- Macquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation, Macquarie University, Sydney, NSW 2109, Australia.
ORCID-Profile: Taoran Liu, Shan Jiang, Yuanyuan Gu, Wai-Kit Ming
Förderung
- SIRG - CityU Strategic Interdisciplinary Research Grant
- SIRG—the CityU Strategic Interdisciplinary Research Grant
Zitieren
APA
Liu, T., Yu, J., Gao, Y., Ma, X., Jiang, S., Gu, Y., & Ming, W. K. (2023). Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers. Cancers, 16(1), 103. https://doi.org/10.3390/cancers16010103
Vancouver
Liu T, Yu J, Gao Y, Ma X, Jiang S, Gu Y, et al. Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers. Cancers. 2023;16(1):103. doi:10.3390/cancers16010103
BibTeX
@article{Liu2023,
author = {Liu, Taoran and Yu, Jing and Gao, Yangyang and Ma, Xinyang and Jiang, Shan and Gu, Yuanyuan and Ming, Wai-Kit},
title = {Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {103},
doi = {10.3390/cancers16010103}
}
EUVIMED